Phase 1/2Recruiting
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Phase I/II, Multi-Center, Open-Label Study of VT3989, Alone or in Combination, in Patients With Locally Advanced or Metastatic Solid Tumors
- Sponsor
- Vivace Therapeutics, Inc (Industry)
- Enrollment
- 434 planned
- Conditions
- Solid Tumor, Adult; Mesothelioma; NSCLC
- Interventions
- VT3989; Nivolumab & Ipilimumab; Osimertinib; Pemetrexed/Carboplatin
- Ages
- adults, older adults
- Registry
- NCT04665206
Full record on ClinicalTrials.gov
From the registry
This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no effective standard therapy is available.
Primary outcomes
- Occurrence of Dose Limiting Toxicity
- Occurrence of General Toxicity
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered